ChiCTR-OCH-13003414 版本V1.0 版本创建时间2016/02/22 22:43:03 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR-OCH-13003414 

最近更新日期:

Date of Last Refreshed on:

2015-05-06 11:42:00 

注册时间:

Date of Registration:

2013-08-05 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

Sigma1R表达变化与非酒精性脂肪性肝病关系

Public title:

The relationship between the expression of sigma-1 receptor and nonalcoholic fatty liver disease

注册题目简写:

English Acronym:

研究课题的正式科学名称:

Sigma1R表达变化与非酒精性脂肪性肝病关系

Scientific title:

A preliminary study on the relationship between the expression of sigma-1 receptor and nonalcoholic fatty liver disease

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

熊吉 

研究负责人:

陈东风 

Applicant:

Ji Xiong 

Study leader:

Dongfeng Chen 

申请注册联系人电话:

Applicant telephone:

+86 15825924201

研究负责人电话:

Study leader's
telephone:

+86 13883032812

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

xjazh@21cn.com

研究负责人电子邮件:

Study leader's E-mail:

chendf1981@126.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

重庆市渝中区长江支路10号

研究负责人通讯地址:

重庆市渝中区长江支路10号

Applicant address:

10 Changjiang Branch Road, Chongqing, China

Study leader's address:

10 Changjiang Branch Road, Chongqing, China

申请注册联系人邮政编码:

Applicant postcode:

400042

研究负责人邮政编码:

Study leader's postcode:

400042

申请人所在单位:

第三军医大学第三附属医院(大坪医院)

Applicant's institution:

Daping Hospital, the Third Military Medical University, Chongqing, China

研究负责人所在单位:

Affiliation of the Leader:

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

医研伦审(2013)第014号

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

第三军医大学第三附属医院医学伦理委员会

Name of the ethic committee:

Ethics Committee of Daping Hospital, the Third Military Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2013-06-27 00:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

第三军医大学第三附属医院(大坪医院)

Primary sponsor:

Daping Hospital, the Third Military Medical University, Chongqing, China

研究实施负责(组长)单位地址:

重庆市渝中区长江支路10号

Primary sponsor's address:

No.10, Changjiang Branch Road, Chongqing, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

经费或物资来源:

第三军医大学第三附属医院(大坪医院)

Source(s) of funding:

Daping Hospital, the Third Military Medical University, Chongqing, China

研究疾病:

非酒精性脂肪性肝病  

Target disease:

Nonalcoholic fatty liver disease

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

I期临床试验 

Study phase:

1

研究设计:

队列研究 

Study design:

Cohort study 

研究目的:

探讨肝脏sigma-1受体的表达变化在非酒精性脂肪性肝病中的作用及其机制  

Objectives of Study:

To explore the effect of hepatic expression of sigma-1 receptor on nonalcoholic fatty liver disease and its mechanism

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.年龄18~60岁;2.临床诊断为胆囊结石患者;3.将接受腹腔镜胆囊切除术;4.签署知情同意书;

Inclusion criteria

1.Aged 18 to 60 years old; 2.Patients with gallbladder stones; 3.patients will undergo laparoscopic cholecystectomy; 4.patients signed the informed consent.

排除标准:

1.男性每日饮酒>20g,女性每日饮酒>10g;2.HBsAg、HCVAb、ANA滴度大于1/160;3.自身免疫性肝病和遗传性肝病;4.药物性肝病;5.吸毒者;

Exclusion criteria:

1.>20 g per day in men and 10 g per day in women; 2.Patients with positive hepatitis B surface antigen, antibody against hepatitis C virus and antinuclear antibody titre >1/160; 3.Patients had autoimmune or genetically induced (hemochromatosis, Wilson's disease or a1-antitrypsin de?ciency) liver disease; 4.injection drug users.

研究实施时间:

Study execute time:

From 2013-08-01 00:00:00 To 2014-08-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2013-08-01 00:00:00 To 2014-08-01 00:00:00

干预措施:

Interventions:

组别:

无非酒精性脂肪性肝病

样本量:

60

Group:

control group

Sample size:

干预措施:

腹腔镜胆囊切除术

干预措施代码:

Intervention:

cholecystectomy by laparoscopy

Intervention code:

组别:

非酒精性脂肪性肝病

样本量:

60

Group:

nonalcoholic fatty liver disease

Sample size:

干预措施:

腹腔镜胆囊切除术

干预措施代码:

Intervention:

cholecystectomy by laparoscopy

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

重庆 

市(区县):

 

Country:

China

Province:

Chongqing

City:

单位(医院):

第三军医大学第三附属医院 

单位级别:

三甲 

Institution
hospital:

Daping Hospital, the Third Military Medical University

Level of the institution:

Tertiary

测量指标:

Outcomes:

指标中文名:

血常规

指标类型:

主要指标

Outcome:

blood routine

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肝功能

指标类型:

主要指标

Outcome:

liver function

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血脂

指标类型:

主要指标

Outcome:

blood fat

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血胰岛素

指标类型:

主要指标

Outcome:

blood insulin

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血胰岛素

指标类型:

主要指标

Outcome:

blood glucos

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 60 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

NA

Randomization Procedure (please state who generates the random number sequence and by what method):

NA

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

数据与安全监察委员会:

Data and Safety Monitoring Committee:

注册人:

Name of Registration:

 2013-08-05 00:00:00